POMC & leptin-receptor deficiency: when the appetite signal is missing from birth

One precursor gone, and three systems fall silent together — the clearest proof that a single melanocortin gene can hold colour, hormones, and hunger in one hand.

If you wanted a single disease to prove that the melanocortin appetite circuit is not a mouse curiosity but a real human control system, this is it. POMC deficiency is what happens when the body cannot make proopiomelanocortin — the precursor protein that is supposed to be cut, tissue by tissue, into the melanocortin hormones. Remove the precursor and you do not lose one signal; you lose all of them at once, and the result is a child whose colouring, hormones, and appetite all point back to the same broken gene.^[3]

One missing precursor, three failures

The hallmark of POMC deficiency is a triad that looks, at first, like three unrelated problems. There is adrenal insufficiency, because ACTH — the POMC peptide that drives the adrenal glands — is missing, and this is the dangerous part, present from the newborn period. There isred hair and pale skin, because α-MSH, the pigment signal, is also cut from POMC: with none of it reaching MC1R, the pigment switch is never flipped to dark, exactly as in a natural redhead with an inactive MC1R gene. And there is severe, early-onset obesity with relentless hunger, because the same α-MSH is missing at MC4R, the brain's appetite brake.^[3]

That the three travel together is the whole point. It is one of biology's cleanest demonstrations that a single precursor is reused across colour, the stress axis, and energy balance — the thesis this entire site is built on, written in a patient.

LEPR deficiency: the neighbouring break

POMC deficiency rarely travels alone in the clinic's thinking, because it has a close neighbour. In leptin-receptor (LEPR) deficiency, the POMC neurons themselves are intact — but they never hear the signal to fire. Leptin, the hormone fat releases to report how full the body's energy stores are, arrives at the arcuate nucleus and finds no working receptor to bind. The POMC neurons stay quiet, α-MSH is not released, and the downstream result is the same picture of unrelenting hunger and severe, early obesity.^[3] One disease removes the precursor; the other removes the switch that should turn the precursor's neurons on. Both end at the same silent MC4R.

Why one drug treats both

This shared endpoint is exactly why a single drug works for both conditions. Setmelanotide is an MC4R agonist: it acts below the break, re-supplying the appetite signal that the missing α-MSH — whether absent because POMC is gone or because the leptin signal never arrived — should have carried. In the pivotal Phase 3 trials, about 80% of participants with POMC deficiency and 45% with LEPR deficiency achieved at least 10% weight loss at roughly a year, alongside large reductions in hunger.^[1] On that basis the FDA approved setmelanotide inNovember 2020 for obesity due to POMC, PCSK1, or LEPR deficiency — its first approval, and the first drug ever cleared for these diseases.^[2]

(PCSK1 deficiency belongs in the same group for the same reason: PCSK1 encodes one of the enzymes that actually cuts POMC into its active peptides, so losing it starves the pathway of α-MSH just as losing POMC itself does.)^[3]

The honest limits

Setmelanotide addresses the appetite arm, and only that arm. The adrenal insufficiency of POMC deficiency is not touched by it and still requires lifelong steroid replacement, managed by an endocrinologist — a reminder that re-supplying one melanocortin signal does not rebuild all the others the missing precursor should have provided.^[3] The drug also carries the melanocortin class's built-in effects, including skin darkening from its action at MC1R and nausea. It is a genuine, disease-specific treatment for a condition that previously had none — not a cure for the underlying genetic defect.

The honest bottom line

POMC and LEPR deficiency are rare, but they carry outsized weight in this field: they are the experiments of nature that showed the leptin–melanocortin circuit really governs human appetite, and they are where setmelanotide — now used far more broadly — first proved itself. For the drug, see setmelanotide; for the receptor it targets, see MC4R; for the wider catalogue of genes that can break this pathway, see the genetics of the system; and for the acquired version of the same problem, see hypothalamic obesity.